Pioglitazone acutely reduces energy metabolism and insulin secretion in rats

Diabetes

Volumn 62, Issue 6, 2013, Pages 2122-2129

  Lamontagne, Julien ^a,b   Jalbert Arsenault, Élise ^a,b   Pepin, Émilie ^a,b   Peyot, Marie Line ^a   Ruderman, Neil B ^c   Nolan, Christopher J ^d   Joly, Erik ^a   Madiraju, S R Murthy ^a   Poitout, Vincent ^b   Prentki, Marc ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c BOSTON MEDICAL CENTER   (United States)

^d The Australian National University   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIMETRY; CONTROLLED STUDY; CORE TEMPERATURE; ENERGY EXPENDITURE; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LUNG GAS EXCHANGE; MALE; METABOLISM; NONHUMAN; OXYGEN CONSUMPTION; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TELEMETRY;

ANIMALS; CALORIMETRY, INDIRECT; ENERGY METABOLISM; GLUCOSE; HYPOGLYCEMIC AGENTS; INSULIN; MALE; OXYGEN CONSUMPTION; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84878262941     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0428     Document Type: Article

References (38)

1. Corkey BE. Banting lecture 2011: hyperinsulinemia: cause or consequence? Diabetes 2012;61:4-13
2. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-1812 (Pubitemid 44033300)
3. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008;31(Suppl 2):S262-S268
4. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet 2011;378:169-181
5. Nyenwe EA, Jerkins TW, Umpierrez GE, Kitabchi AE. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism 2011;60:1-23
6. Ye JM, Dzamko N, Cleasby ME, et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 2004;47:1306-1313 (Pubitemid 39093328)
7. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006;116:581-589 (Pubitemid 43326862)
8. Gupta D, Kono T, Evans-Molina C. The role of peroxisome proliferatoractivated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2010;12:1036-1047
9. Lamontagne J, Pepin E, Peyot ML, et al. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic betacell at submaximal glucose concentrations. Endocrinology 2009;150:3465-3474
10. Brunmair B, Staniek K, Gras F, et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 2004;53:1052-1059 (Pubitemid 38436618)
11. Andrikopoulos S. Obesity and type 2 diabetes: slow down!-Can metabolic deceleration protect the islet beta cell from excess nutrient-induced damage? Mol Cell Endocrinol 2010;316:140 -146
12. Aston-Mourney K, Proietto J, Morahan G, Andrikopoulos S. Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. Diabetologia 2008;51:540-545
13. Hagman DK, Latour MG, Chakrabarti SK, et al. Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets. Diabetes 2008;57:424-431
14. Dutil J, Deng AY. Further chromosomal mapping of a blood pressure QTL in Dahl rats on chromosome 2 using congenic strains. Physiol Genomics 2001;6:3 -9
15. Goh TT, Mason TM, Gupta N, et al. Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure. Am J Physiol Endocrinol Metab 2007;292:E549-E560 (Pubitemid 46220580)
16. Makimura H, Mizuno TM, Yang XJ, Silverstein J, Beasley J, Mobbs CV. Cerulenin mimics effects of leptin on metabolic rate, food intake, and body weight independent of the melanocortin system, but unlike leptin, cerulenin fails to block neuroendocrine effects of fasting. Diabetes 2001;50:733-739 (Pubitemid 32242628)
17. Hohmeier HE, Mulder H, Chen G, Henkel-Rieger R, Prentki M, Newgard CB. Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 2000;49:424-430 (Pubitemid 30131788)
18. Gotoh M, Maki T, Satomi S, et al. Reproducible high yield of rat islets by stationary in vitro digestion following pancreatic ductal or portal venous collagenase injection. Transplantation 1987;43:725-730 (Pubitemid 17075344)
19. Uwaifo GI, Parikh SJ, Keil M, Elberg J, Chin J, Yanovski JA. Comparison of insulin sensitivity, clearance, and secretion estimates using euglycemic and hyperglycemic clamps in children. J Clin Endocrinol Metab 2002;87:2899-2905 (Pubitemid 34655360)
20. Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58:192 -200
21. Henke BR, Blanchard SG, Brackeen MF, et al. N-(2-Benzoylphenyl)-Ltyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem 1998;41:5020 - 5036
22. Lin CH, Peng YH, Coumar MS, et al. Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists. J Med Chem 2009;52:2618-2622
23. Campbell IW, Mariz S. Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007;76:163-176
24. Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000;49:735-740 (Pubitemid 30339988)
25. Kim SH, Abbasi F, Chu JW, et al. Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005;54:2447-2452 (Pubitemid 41134274)
26. Farret A, Chevassus H, Roux B, Petit P, Galtier F. Direct rosiglitazone-induced modifications in insulin secretion, action and clearance: a singledose hyperglycaemic clamp study. Diabetologia 2007;50:1384-1387 (Pubitemid 46879011)
27. Osei K, Gaillard T, Schuster D. Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone. Metabolism 2007;56:24-29 (Pubitemid 44855009)
28. LeBrasseur NK, Kelly M, Tsao TS, et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am J Physiol Endocrinol Metab 2006;291:E175-E181 (Pubitemid 44035323)
29. Blalock EM, Phelps JT, Pancani T, et al. Effects of long-term pioglitazone treatment on peripheral and central markers of aging. PLoS ONE 2010;5:e10405
30. Syversen U, Stunes AK, Gustafsson BI, et al. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone. BMC Endocr Disord 2009;9:10
31. Calixto LA, de Oliveira AR, Jabor VA, Bonato PS. In vitro characterization of rosiglitazone metabolites and determination of the kinetic parameters employing rat liver microsomal fraction. Eur J Drug Metab Pharmacokinet 2011;36:159-166
32. Stephenne X, Foretz M, Taleux N, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia 2011;54:3101-3110
33. Foretz M, Hébrard S, Leclerc J, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010;120:2355-2369
34. Ruderman NB, Park H, Kaushik VK, et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003;178:435-442 (Pubitemid 36960435)
35. Wei S, Kulp SK, Chen CS. Energy restriction as an antitumor target of thiazolidinediones. J Biol Chem 2010;285:9780-9791
36. Gohil VM, Sheth SA, Nilsson R, et al. Nutrient-sensitized screening for drugs that shift energy metabolism from mitochondrial respiration to glycolysis. Nat Biotechnol 2010;28:249-255
37. Dhahbi JM, Mote PL, Fahy GM, Spindler SR. Identi fication of potential caloric restriction mimetics by microarray profiling. Physiol Genomics 2005;23:343-350 (Pubitemid 44437970)
38. Nolan CJ, Prentki M. The islet beta-cell: fuel responsive and vulnerable. Trends Endocrinol Metab 2008;19:285-291